Stock Events

Stock Events

Faeth Therapeutics 

$39.00
27
-$0.12-0.31% Thursday 20:00
-$0.60-1.54%Thursday 23:44After hours

Statistics

Day High
39.25
Day Low
38.13
52W High
40.89
52W Low
7.45
Volume
4,386
Avg. Volume
-
Mkt Cap
1.01B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q1 2026
Q2 2026
Next
-131.45
-87.84
-44.23
-0.62
Expected EPS
-0.795018
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-21.09MNet Income

Analyst Ratings

55.90Average Price Target
The highest estimate is 60.00.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech competes in the immunotherapy space, focusing on personalized cancer vaccines which is similar to Sensei's approach in targeting cancer.
Moderna
MRNA
Mkt Cap55.09B
Moderna is involved in mRNA-based therapies, including cancer vaccines, competing in the same immunotherapy field as Sensei.
Novavax
NVAX
Mkt Cap1.53B
Novavax, though primarily known for its work on vaccines, is exploring cancer vaccine candidates, making it a competitor in the immunotherapy space.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, with its acquisition of Kite Pharma, has a strong presence in the cell therapy and immunotherapy market, directly competing with Sensei's cancer treatment strategies.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a diverse portfolio in oncology, including immunotherapies, which pits it against Sensei in the race for effective cancer treatments.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb, with its extensive range of immunotherapy treatments including Opdivo, competes in the same space as Sensei, focusing on innovative cancer therapies.
Merck
MRK
Mkt Cap366B
Merck is a key player in the immunotherapy market with its blockbuster drug Keytruda, making it a direct competitor to Sensei's cancer immunotherapy efforts.
Pfizer
PFE
Mkt Cap159.36B
Pfizer, with its investments in cancer research and immunotherapy, including partnerships for vaccine development, competes in the same arena as Sensei.
Novartis
NVS
Mkt Cap292.35B
Novartis has a strong focus on innovative medicines, including immunotherapies for cancer, making it a competitor in the same field as Sensei.

About

Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
Show more...
CEO
Anand Parikh
Employees
29
Country
United States
ISIN
US81728A2078
WKN
000A41A4Z

Listings

MU
DE
407.MU
XNAS
US
FTH
F
DE
4070.F
STU
DE
4070.STU

0 Comments

Share your thoughts

FAQ

What is Faeth Therapeutics stock price today?▼
The current price of FTH is $39.00 USD — it has decreased by -0.31% in the past 24 hours. Watch Faeth Therapeutics stock price performance more closely on the chart.
What is Faeth Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Faeth Therapeutics stocks are traded under the ticker FTH.
What is Faeth Therapeutics market cap?▼
Today Faeth Therapeutics has the market capitalization of 1.01B
When is the next Faeth Therapeutics earnings date?▼
Faeth Therapeutics is going to release the next earnings report on November 10, 2026.
What were Faeth Therapeutics earnings last quarter?▼
FTH earnings for the last quarter are -2.84 USD per share, whereas the estimation was -2.64 USD resulting in a -7.74% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Faeth Therapeutics revenue for the last year?▼
Faeth Therapeutics revenue for the last year amounts to 0 USD.
What is Faeth Therapeutics net income for the last year?▼
FTH net income for the last year is -21.09M USD.
How many employees does Faeth Therapeutics have?▼
As of September 04, 2026, the company has 29 employees.
In which sector is Faeth Therapeutics located?▼
Faeth Therapeutics operates in the Health & Wellness sector.
When did Faeth Therapeutics complete a stock split?▼
The last stock split for Faeth Therapeutics was on June 17, 2025 with a ratio of 1:20.
Where is Faeth Therapeutics headquartered?▼
Faeth Therapeutics is headquartered in AUSTIN, United States.